Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19

Abstract The prospective observational cohort study COMPASS-COVID-19 aimed to develop a risk assessment model for early identification of hospitalized COVID-19 patients at risk for worsening disease. Patients with confirmed COVID-19 (n = 430) hospitalized between March 18 and April 21, 2020 were divided in derivation (n = 310) and validation (n = 120) cohorts. Two groups became evident: (1) good prognosis group (G-group) with patients hospitalized at the conventional COVID-19 ward and (2) Worsening disease group (W-group) with patients admitted to the intensive care unit (ICU) from the emergency departments. The study end point was disease worsening (acute respiratory failure, shock, myocardial dysfunction, bacterial or viral coinfections, and acute kidney injury) requiring ICU admission. All patients were routinely evaluated for full blood count, prothrombin time, fibrinogen, D-dimers, antithrombin (AT), and protein C activity. Data from the first hospitalization day at the conventional ward or the ICU were analyzed. Cardiovascular risk factors and comorbidities were routinely registered. Obesity, hypertension, diabetes and male gender, increased fibrinogen and D-dimers, thrombocytopenia, AT deficiency, lymphopenia, and an International Society on Thrombosis and Haemostasis (ISTH) score for compensated disseminated intravascular coagulation score (cDIC-ISTH) ≥5 were significant risk factors for worsening disease. The COMPASS-COVID-19 score was derived from multivariate analyses and includes obesity, gender, hemoglobin, lymphocyte, and the cDIC-ISTH score (including platelet count, prothrombin time, D-dimers, AT, and protein C levels). The score has a very good discriminating capacity to stratify patients at high and low risk for worsening disease, with an area under the receiver operating characteristic curve value of 0.77, a sensitivity of 81%, and a specificity of 60%. Application of the COMPASS-COVID-19 score at the validation cohort showed 96% sensitivity. The COMPASS-COVID-19 score is an accurate clinical decision-making tool for an easy identification of COVID-19 patients being at high risk for disease worsening.

[1]  Amit N. Patel,et al.  Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 , 2020, The New England journal of medicine.

[2]  Yi Wang,et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.

[3]  S. Birocchi,et al.  Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified? , 2020, Thrombosis and Haemostasis.

[4]  Hangyuan Guo,et al.  Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis , 2020, Journal of Infection.

[5]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[6]  W. Alhazzani,et al.  COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine , 2020, Journal of Clinical Epidemiology.

[7]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[8]  F. Tubach,et al.  Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19 , 2020, Qeios.

[9]  K. Syrigos,et al.  Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action , 2020, British journal of haematology.

[10]  Lynnette Brammer,et al.  Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[11]  Theodora Psaltopoulou,et al.  Hematological findings and complications of COVID‐19 , 2020, American journal of hematology.

[12]  Jing Shi,et al.  Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan , 2020, Journal of Allergy and Clinical Immunology.

[13]  Erwan L'Her,et al.  Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[14]  H. Kauczor,et al.  The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society , 2020, Radiology.

[15]  M. Nishimura,et al.  Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations , 2020, The Lancet Respiratory Medicine.

[16]  Jing Yuan,et al.  Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.

[17]  A. Davis,et al.  Management of Critically Ill Adults With COVID-19. , 2020, JAMA.

[18]  A. Falanga,et al.  ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[19]  G. Onder,et al.  Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. , 2020, JAMA.

[20]  J. Patel,et al.  COVID-19 and the liver: little cause for concern , 2020, The Lancet Gastroenterology & Hepatology.

[21]  E. Rubin,et al.  Covid-19 — The Search for Effective Therapy , 2020, The New England journal of medicine.

[22]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[23]  Giuseppe Biondi-Zoccai,et al.  Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic , 2020, Journal of the American College of Cardiology.

[24]  Yu Zhou,et al.  Predicting COVID-19 malignant progression with AI techniques , 2020, medRxiv.

[25]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[26]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[27]  Runsheng Wang,et al.  Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study , 2020, American journal of respiratory and critical care medicine.

[28]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[29]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[30]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[31]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[32]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[33]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[34]  Gary S Collins,et al.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration , 2015, Annals of Internal Medicine.

[35]  K. Moons,et al.  Diagnostic and prognostic prediction models , 2013, Journal of thrombosis and haemostasis : JTH.

[36]  J. Concato,et al.  A simulation study of the number of events per variable in logistic regression analysis. , 1996, Journal of clinical epidemiology.

[37]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[38]  Richard D Riley,et al.  Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal , 2020 .

[39]  Jing Cao,et al.  A Tool for Early Prediction of Severe Coronavirus Disease 2019 (COVID-19): A Multicenter Study Using the Risk Nomogram in Wuhan and Guangdong, China , 2020 .

[40]  Ping-yan Chen,et al.  Weighted Youden index and its two-independent-sample comparison based on weighted sensitivity and specificity. , 2013, Chinese medical journal.